Collaborative projects supported by private and public investors: Pherecydes Pharma is financed by investment funds, private investors and receives regional, national and European subsidies.
Partnerships to accelerate the development of phagotherapy: the pooling of internal and external expertise is a catalyst for more efficient research and development.
PhagoPROD is one of Pherecydes Pharma’s initiatives aimed at implementing all the production procedures required to produce phages in accordance with Good Manufacturing Practices (GMP). This project is supported by Horizon 20/20 funding from the European Union. Click here to learn more about PhagoPROD.
Pherecydes Pharma has been conducting research and development projects with public institutes, hospitals and private companies for many years. In the context of its future projects, the Company may be interested in new production and administration technologies, as well as new animal models of infectious pathologies.
Expertise in diagnosis development and automation is also a key area of focus for future partnerships.
Since its creation, Pherecydes Pharma has benefited from the financial support of several regional, national and European institutions.